Open App →
Back to News Feed
Korea Times November 4, 2026 By yonhap@koreatimes.co.kr(KoreaTimes) positive

SKT's operating profit up over 1,000%, turns to black in Q3

AI / LLMData Center
SK Telecom (SKT), Korea's top mobile service carrier, said Wednesday its third-quarter operating profit surged 1,041.3 percent from a year earlier, while its net profit shifted to the black during the same period. Operating income for the July-September period was 552.3 billion won ($411.4 million), while sales rose 13.1 percent on-year to 4.49 trillion won. Net profit was 411.8 billion won, shifting from a loss of 166.7 billion won the previous year. SK Telecom said the steady growth of its main mobile service business, as well as the rise of new ventures involving artificial intelligence (AI), helped improve its performance during the three-month period. Sales from its AI data centers rose 6.2 percent on-year, while those from other AI-related businesses were up 27.3 percent from a year earlier, the company said. The wireless carrier founded two new wholly owned subsidiaries — SK Hyper and SK Horizon — in July and August, respectively, to oversee its AI data center business. SK Hyper is constructing AI data centers in the southern region of Ulsan and Seoul, of which combined capacit
Read original article ↗

Related Articles

Integrated Storage Empowering Edge AI | Longsys präsentiert sich auf der electronica 2026

MÜNCHEN, 4. November 2026 /PRNewswire/ -- Die electronica 2026 findet vom 10. bis 13. November in München statt. Da sich

PR Newswire · November 4, 2026

GigaDevice sees tight niche DRAM supply, slower price gains

AI demand continues to heat up while major global memory makers shift capacity toward higher-value products, keeping nic

Digitimes · November 4, 2026

Decoy processors carry Korean HBM past US export controls into China

A loophole in US export controls reportedly lets high-bandwidth memory (HBM) made by Samsung Electronics and SK Hynix re

Digitimes · November 4, 2026

HLB liver cancer drug enters FDA review, decision expected by April

Korean biopharmaceutical group HLB is getting a second shot at U.S. Food and Drug Administration (FDA) approval for its

Korea Times · November 4, 2026